Methodological considerations for measuring biofluid-based microRNA biomarkers

Brian N. Chorley; Elnaz Atabakhsh; Graeme Doran; Jean Charles Gautier; Heidrun Ellinger-Ziegelbauer; David Jackson; Tatiana Sharapova; Peter S.T. Yuen; Rachel J. Church; Philippe Couttet; Roland Froetschl; James McDuffie; Victor Martinez; Parimal Pande; Lauren Peel; Conor Rafferty; Frank J. Simutis; Alison H. Harrill

doi:10.1080/10408444.2021.1907530

Methodological considerations for measuring biofluid-based microRNA biomarkers

Brian N. Chorley, Elnaz Atabakhsh, Graeme Doran, Jean Charles Gautier, Heidrun Ellinger-Ziegelbauer, David Jackson, Tatiana Sharapova, Peter S.T. Yuen, Rachel J. Church, Philippe Couttet, Roland Froetschl, James McDuffie, Victor Martinez, Parimal Pande, Lauren Peel, Conor Rafferty, Frank J. Simutis, Alison H. Harrill

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological status. There has thus been great enthusiasm for developing miRNAs as biomarkers of adverse outcomes for scientific, regulatory, and clinical purposes. Despite advances in measurement capabilities for miRNAs, miRNAs are still not routinely employed as noninvasive biomarkers. This is in part due to the lack of standard approaches for sample preparation and miRNA measurement and uncertainty in their biological interpretation. Members of the microRNA Biomarkers Workgroup within the Health and Environmental Sciences Institute’s (HESI) Committee on Emerging Systems Toxicology for the Assessment of Risk (eSTAR) are a consortium of private- and public-sector scientists dedicated to developing miRNAs as applied biomarkers. Here, we explore major impediments to routine acceptance and use of miRNA biomarkers and case examples of successes and deficiencies in development. Finally, we provide insight on miRNA measurement, collection, and analysis tools to provide solid footing for addressing knowledge gaps toward routine biomarker use.

Original language	English
Pages (from-to)	264-282
Number of pages	19
Journal	Critical Reviews in Toxicology
Volume	51
Issue number	3
DOIs	https://doi.org/10.1080/10408444.2021.1907530
Publication status	Published - 2021
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported, in part, by internal funding from the Intramural Research Program of the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases [grant Z01 DK043400] and the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency Office of Research and Development, and the U.S. Army Medical Research and Development Command, Military Operational Medicine Research Program. The authors sincerely thank Ms. Carolina Morell-Perez of HESI for her kind assistance with preparation and external peer review of the manuscript prior to submission. The authors acknowledge Drs. Sheau-Fung Thai, Weichun Huang, Katie O’Shaughnessy, and Maureen Gwinn of the US EPA, Liwen Liu and Kevin Gerrish of the NIEHS, and Alison Sanders of the Icahn School of Medicine at Mount Sinai for constructive comments on this manuscript. The authors gratefully acknowledge the comments offered by three reviewers selected by the Editor. The comments of these reviewers who were anonymous to the authors helped improve the clarity and content of the manuscript.

Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

ASJC Scopus Subject Areas

Toxicology

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, Non-P.H.S.

Access to Document

10.1080/10408444.2021.1907530

Cite this

Chorley, B. N., Atabakhsh, E., Doran, G., Gautier, J. C., Ellinger-Ziegelbauer, H., Jackson, D., Sharapova, T., Yuen, P. S. T., Church, R. J., Couttet, P., Froetschl, R., McDuffie, J., Martinez, V., Pande, P., Peel, L., Rafferty, C., Simutis, F. J., & Harrill, A. H. (2021). Methodological considerations for measuring biofluid-based microRNA biomarkers. Critical Reviews in Toxicology, 51(3), 264-282. https://doi.org/10.1080/10408444.2021.1907530

Chorley, BN, Atabakhsh, E, Doran, G, Gautier, JC, Ellinger-Ziegelbauer, H, Jackson, D, Sharapova, T, Yuen, PST, Church, RJ, Couttet, P, Froetschl, R, McDuffie, J, Martinez, V, Pande, P, Peel, L, Rafferty, C, Simutis, FJ & Harrill, AH 2021, 'Methodological considerations for measuring biofluid-based microRNA biomarkers', Critical Reviews in Toxicology, vol. 51, no. 3, pp. 264-282. https://doi.org/10.1080/10408444.2021.1907530

@article{5a6ae258bf994307bee42ec555f0c3d2,

title = "Methodological considerations for measuring biofluid-based microRNA biomarkers",

abstract = "MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological status. There has thus been great enthusiasm for developing miRNAs as biomarkers of adverse outcomes for scientific, regulatory, and clinical purposes. Despite advances in measurement capabilities for miRNAs, miRNAs are still not routinely employed as noninvasive biomarkers. This is in part due to the lack of standard approaches for sample preparation and miRNA measurement and uncertainty in their biological interpretation. Members of the microRNA Biomarkers Workgroup within the Health and Environmental Sciences Institute{\textquoteright}s (HESI) Committee on Emerging Systems Toxicology for the Assessment of Risk (eSTAR) are a consortium of private- and public-sector scientists dedicated to developing miRNAs as applied biomarkers. Here, we explore major impediments to routine acceptance and use of miRNA biomarkers and case examples of successes and deficiencies in development. Finally, we provide insight on miRNA measurement, collection, and analysis tools to provide solid footing for addressing knowledge gaps toward routine biomarker use.",

author = "Chorley, {Brian N.} and Elnaz Atabakhsh and Graeme Doran and Gautier, {Jean Charles} and Heidrun Ellinger-Ziegelbauer and David Jackson and Tatiana Sharapova and Yuen, {Peter S.T.} and Church, {Rachel J.} and Philippe Couttet and Roland Froetschl and James McDuffie and Victor Martinez and Parimal Pande and Lauren Peel and Conor Rafferty and Simutis, {Frank J.} and Harrill, {Alison H.}",

note = "Funding Information: This work was supported, in part, by internal funding from the Intramural Research Program of the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases [grant Z01 DK043400] and the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency Office of Research and Development, and the U.S. Army Medical Research and Development Command, Military Operational Medicine Research Program. The authors sincerely thank Ms. Carolina Morell-Perez of HESI for her kind assistance with preparation and external peer review of the manuscript prior to submission. The authors acknowledge Drs. Sheau-Fung Thai, Weichun Huang, Katie O{\textquoteright}Shaughnessy, and Maureen Gwinn of the US EPA, Liwen Liu and Kevin Gerrish of the NIEHS, and Alison Sanders of the Icahn School of Medicine at Mount Sinai for constructive comments on this manuscript. The authors gratefully acknowledge the comments offered by three reviewers selected by the Editor. The comments of these reviewers who were anonymous to the authors helped improve the clarity and content of the manuscript. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2021",

doi = "10.1080/10408444.2021.1907530",

language = "English",

volume = "51",

pages = "264--282",

journal = "Critical Reviews in Toxicology",

issn = "1040-8444",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Methodological considerations for measuring biofluid-based microRNA biomarkers

AU - Chorley, Brian N.

AU - Atabakhsh, Elnaz

AU - Doran, Graeme

AU - Gautier, Jean Charles

AU - Ellinger-Ziegelbauer, Heidrun

AU - Jackson, David

AU - Sharapova, Tatiana

AU - Yuen, Peter S.T.

AU - Church, Rachel J.

AU - Couttet, Philippe

AU - Froetschl, Roland

AU - McDuffie, James

AU - Martinez, Victor

AU - Pande, Parimal

AU - Peel, Lauren

AU - Rafferty, Conor

AU - Simutis, Frank J.

AU - Harrill, Alison H.

N1 - Funding Information: This work was supported, in part, by internal funding from the Intramural Research Program of the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases [grant Z01 DK043400] and the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency Office of Research and Development, and the U.S. Army Medical Research and Development Command, Military Operational Medicine Research Program. The authors sincerely thank Ms. Carolina Morell-Perez of HESI for her kind assistance with preparation and external peer review of the manuscript prior to submission. The authors acknowledge Drs. Sheau-Fung Thai, Weichun Huang, Katie O’Shaughnessy, and Maureen Gwinn of the US EPA, Liwen Liu and Kevin Gerrish of the NIEHS, and Alison Sanders of the Icahn School of Medicine at Mount Sinai for constructive comments on this manuscript. The authors gratefully acknowledge the comments offered by three reviewers selected by the Editor. The comments of these reviewers who were anonymous to the authors helped improve the clarity and content of the manuscript. Publisher Copyright: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

N2 - MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological status. There has thus been great enthusiasm for developing miRNAs as biomarkers of adverse outcomes for scientific, regulatory, and clinical purposes. Despite advances in measurement capabilities for miRNAs, miRNAs are still not routinely employed as noninvasive biomarkers. This is in part due to the lack of standard approaches for sample preparation and miRNA measurement and uncertainty in their biological interpretation. Members of the microRNA Biomarkers Workgroup within the Health and Environmental Sciences Institute’s (HESI) Committee on Emerging Systems Toxicology for the Assessment of Risk (eSTAR) are a consortium of private- and public-sector scientists dedicated to developing miRNAs as applied biomarkers. Here, we explore major impediments to routine acceptance and use of miRNA biomarkers and case examples of successes and deficiencies in development. Finally, we provide insight on miRNA measurement, collection, and analysis tools to provide solid footing for addressing knowledge gaps toward routine biomarker use.

AB - MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological status. There has thus been great enthusiasm for developing miRNAs as biomarkers of adverse outcomes for scientific, regulatory, and clinical purposes. Despite advances in measurement capabilities for miRNAs, miRNAs are still not routinely employed as noninvasive biomarkers. This is in part due to the lack of standard approaches for sample preparation and miRNA measurement and uncertainty in their biological interpretation. Members of the microRNA Biomarkers Workgroup within the Health and Environmental Sciences Institute’s (HESI) Committee on Emerging Systems Toxicology for the Assessment of Risk (eSTAR) are a consortium of private- and public-sector scientists dedicated to developing miRNAs as applied biomarkers. Here, we explore major impediments to routine acceptance and use of miRNA biomarkers and case examples of successes and deficiencies in development. Finally, we provide insight on miRNA measurement, collection, and analysis tools to provide solid footing for addressing knowledge gaps toward routine biomarker use.

UR - http://www.scopus.com/inward/record.url?scp=85106501803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106501803&partnerID=8YFLogxK

U2 - 10.1080/10408444.2021.1907530

DO - 10.1080/10408444.2021.1907530

M3 - Review article

C2 - 34038674

AN - SCOPUS:85106501803

SN - 1040-8444

VL - 51

SP - 264

EP - 282

JO - Critical Reviews in Toxicology

JF - Critical Reviews in Toxicology

IS - 3

ER -

Methodological considerations for measuring biofluid-based microRNA biomarkers

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this